Skip to main
PEPG
PEPG logo

PepGen Inc (PEPG) Stock Forecast & Price Target

PepGen Inc (PEPG) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 40%
Hold 0%
Sell 20%
Strong Sell 0%

Bulls say

PepGen Inc. is demonstrating a positive outlook due to the encouraging early data from its FREEDOM-DM1 trial, which showed a dose-dependent increase in splicing correction following treatment, achieving a notable 29.1% splicing correction, surpassing the therapeutic benefit threshold. The company's Enhanced Delivery Oligonucleotide (EDO) platform has proven effective in achieving significant tissue penetration and cellular uptake, with nearly a four-fold increase in oligonucleotide enrichment in muscle tissue when comparing different dosing levels. Additionally, the absence of safety issues reported at dosages tested reinforces confidence in the EDO platform and the overall potential of PepGen's pipeline, particularly for its DM1 program.

Bears say

PepGen Inc. reported a net loss of $22 million, or $0.68 per share, in the fourth quarter of 2024, indicating significant financial strain. The company has reduced its probability of success for its flagship product, PGN-EDO51, from 40% to 25% due to safety concerns related to kidney function, which also included the removal of a 15% premium related to its risk-reward profile. Key risks tied to PepGen's outlook involve the potential failure of PGN-EDO51 in clinical studies, obstacles to securing regulatory approval in both the US and EU, and the inability to meet projected peak commercial revenue estimates, all of which cast doubt on the company's future financial performance.

PepGen Inc (PEPG) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 20% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PepGen Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PepGen Inc (PEPG) Forecast

Analysts have given PepGen Inc (PEPG) a Buy based on their latest research and market trends.

According to 5 analysts, PepGen Inc (PEPG) has a Buy consensus rating as of Jul 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PepGen Inc (PEPG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.